202 related articles for article (PubMed ID: 20019983)
21. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
22. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
[TBL] [Abstract][Full Text] [Related]
24. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
Brake M; Loertzer H; Horsch R; Keller H
Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
[TBL] [Abstract][Full Text] [Related]
26. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
27. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
Ferro M; Katalin MO; Buonerba C; Marian R; Cantiello F; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Del Giudice F; Perdonà S; Del Prete P; Mirone V; Borghesi M; Porreca A; Artibani W; Bove P; Lima E; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Ditonno P; Serretta V; Russo GI; Terracciano D; di Lorenzo G; Damiano R; Sonpavde G; Vartolomei MD; de Cobelli O; Lucarelli G
Urol Oncol; 2020 May; 38(5):459-464. PubMed ID: 32173242
[TBL] [Abstract][Full Text] [Related]
28. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
[TBL] [Abstract][Full Text] [Related]
29. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
30. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
31. How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?
Yun SJ; Kim SK; Kim WJ
Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S44-51. PubMed ID: 27326407
[TBL] [Abstract][Full Text] [Related]
32. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
[TBL] [Abstract][Full Text] [Related]
33. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
34. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
35. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
36. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
37. Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
Kikuchi E; Hayakawa N; Fukumoto K; Shigeta K; Matsumoto K
Int J Urol; 2020 Feb; 27(2):108-116. PubMed ID: 31793703
[TBL] [Abstract][Full Text] [Related]
38. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder.
Esrig D; Freeman JA; Stein JP; Skinner DG
Semin Urol Oncol; 1997 Aug; 15(3):154-60. PubMed ID: 9394910
[TBL] [Abstract][Full Text] [Related]
39. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
[TBL] [Abstract][Full Text] [Related]
40. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]